Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05

Eric R. Siegel

High Impact

Biostatistician II

Also affiliated: Tufts University (1981); University of Maryland, Baltimore (2018); Greater Baltimore Medical Center (2018); St. Michael's Hospital (2012); Arkansas Children's Hospital (2026); Charleston Area Medical Center (2011); Johns Hopkins University (2018); University of Toronto (2012); New York Hall of Science (1998); University of Arkansas Medical Center (2003–2024); Johns Hopkins Medicine (2018); Princess Margaret Cancer Centre (2012); Yale University (2018); Central Arkansas Veterans Healthcare System (2001–2017); National Cancer Institute (2002); John L. McClellan Memorial Veterans Hospital (2005–2006); Hôpital d'Hautepierre (2020); Nortek (United States) (2007); University of Virginia (2023); University of Oklahoma (2003)

52 h-index 430 pubs 10,228 cited

  • Humans
  • Female
  • Middle Aged
  • Male
  • Adult
  • Aged
  • Retrospective Studies
  • Animals
  • Aged, 80 and over
  • Pregnancy
  • Mice
  • Treatment Outcome
  • Breast Neoplasms
  • Neoplasm Recurrence, Local
  • Multiple Myeloma

Biography and Research Information

OverviewAI-generated summary

Eric R. Siegel's research has focused on various aspects of cancer treatment and disease management, particularly in the context of hematological malignancies and gynecological cancers. He has investigated the thrombogenic activity of specific chemotherapy drugs, such as doxorubicin, in patients with multiple myeloma receiving thalidomide, and has explored the increased risk of deep-vein thrombosis associated with these treatments.

Siegel has also contributed to studies on the efficacy of different therapeutic regimens for uterine serous carcinomas, including randomized phase II trials comparing carboplatin-paclitaxel with carboplatin-paclitaxel-trastuzumab in cases overexpressing HER2/neu. His work includes analyses of autologous stem cell transplantation outcomes in multiple myeloma patients, with a particular focus on elderly patients and those with renal failure.

Beyond clinical oncology, Siegel's research has touched upon molecular mechanisms underlying stress resistance and longevity in model organisms, such as C. elegans mutants, by studying the modulation of lipid biosynthesis. With a career marked by extensive publication and high citation counts, he leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 52
  • Publications: 430
  • Citations: 10,228

Positions

  • Biostatistician II 2026–present
    University of Arkansas for Medical Sciences Biostatistics ORCID
  • Biostatistics Project Manager 2017–2026
    University of Arkansas for Medical Sciences Biostatistics ORCID
  • Research Associate 1999–2017
    University of Arkansas for Medical Sciences Biostatistics ORCID

Selected Publications

  • Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
    JAMA Oncology 7 citations DOI OpenAlex
  • A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses (2025)
    2 citations DOI OpenAlex
  • Does Patient Health Literacy Affect Patient Reported Outcome Measure Completion Method in Orthopaedic Patients? (2025)
    Geriatric Orthopaedic Surgery & Rehabilitation 9 citations DOI OpenAlex
  • A customized bed based stand alone array of optically pumped magnetometers for fetal magnetocardiography measurements (2025)
    Scientific Reports 10 citations DOI OpenAlex
  • Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
    4 citations DOI OpenAlex
  • N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID (2025)
    3 citations DOI OpenAlex
  • Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
    Blood Advances 6 citations DOI OpenAlex
  • Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
    Blood Cancer Journal 38 citations DOI OpenAlex
  • Does Body Mass Index Affect the Success of Two-Stage Management of Periprosthetic Joint Infection? (2024)
    2 citations DOI OpenAlex
  • Younger and rural children are more likely to be hospitalized for SARS-CoV-2 infections (2024)
    3 citations DOI OpenAlex
  • Pediatric Off-Road Vehicle Injuries (2024)
    2 citations DOI OpenAlex
  • CB-839 induces reversible dormancy in lung tumor-cells (2024)
    European Journal of Pharmacology 8 citations DOI OpenAlex
  • Correlating maternal and cord-blood inflammatory markers and BDNF with human fetal brain activity recorded by magnetoencephalography: An exploratory study (2024)
    3 citations DOI OpenAlex
  • Fetal magnetocardiographic recordings with a prototype bed-based array system of optically-pumped magnetometers (2024)
    Medical Engineering & Physics 11 citations DOI OpenAlex
  • Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix (2024)
    Proceedings of the National Academy of Sciences 20 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

759 Collaborators 149 Institutions 15 Countries

Top Collaborators

View profile →
View profile →

Similar Researchers

Based on overlapping research topics